CDC's 22nd Director Flags Burnout and Zombie Programs

On August 19, 2026, Dr. Erica Schwartz, the 22nd director of the Centers for Disease Control and Prevention, used her first all-hands staff meeting to acknowledge what many inside the agency have known for months: congressionally funded programs are operating without adequate staff, and employees are burned out and overloaded. Schwartz, who started in the role the previous week after a series of temporary directors, told staff she would meet with them to understand the scope of the dysfunction, but stopped short of announcing concrete fixes for the so-called "zombie" programs that retain appropriations yet are functionally dead because the workers who ran them were laid off by President Donald Trump's administration or remain on leave. Her remarks, captured in a recording heard by the Associated Press, combined candor about problems with a promise of advocacy and a pledge of "radical transparency, scientific rigor and honest communications." The acknowledgment is significant because it comes from a permanent CDC leader after a prolonged leadership vacuum, and it confirms that the agency's operational capacity has been hollowed out at a time when public health threats remain highly visible. The staffing damage Schwartz inherited is not abstract. The AP story she referenced identified CDC programs with congressional appropriations that are nearly dead in practice, a disconnect between budget and execution that undermines core functions such as disease surveillance, outbreak response, laboratory coordination, and guidance development. Health systems, state and local health departments, laboratories, and health IT vendors depend on CDC data and protocols. When the agency cannot staff appropriated programs, the downstream effect is slower detection of emerging pathogens, degraded data flows, and uncertainty for clinical and public health partners. Schwartz's background in the U.S. Coast Guard and U.S. Public Health Service shapes her approach. She signaled that disagreements with U.S. Health Secretary Robert F. Kennedy Jr. would be handled privately, "not in front of the media," because that is part of her uniformed service ethos. This stance creates a tension with her promise of radical transparency. Health policy observers will watch whether private dissent can coexist with public accountability, especially if HHS policy diverges from scientific consensus or CDC's statutory mission. Her language echoing Kennedy's preferred phrases may reassure political leadership, but it also raises questions about how independently the new director will operate. For CDC career staff, the meeting offered recognition but little immediate relief. Schwartz said "the good news is, I'm here" and noted that advocacy was hard under a leadership vacuum, suggesting she intends to fight for resources. Yet the absence of a specific plan for restoring laid-off staff, unfreezing programs, or reducing burnout leaves the agency in a waiting posture. Employees who feel exhausted and overloaded may need more than listening sessions to remain in place, and further attrition would compound the capacity problem. The broader public health community will be watching whether Schwartz can convert diagnostic candor into structural repair. Her confirmation hearing on July 15, 2026, before the Senate Health, Education, Labor and Pensions Committee was a formal milestone, but the all-hands meeting on August 19 was the first test of her internal credibility. If she can secure rehiring authority, restore appropriated programs, and rebuild workforce morale, the CDC could regain some of its diminished standing. If she cannot, the agency risks continuing as a diminished institution with formal responsibilities it lacks the staff to fulfill. The coming weeks will be decisive, as Schwartz begins the meetings she promised with CDC staffers to learn what can be done. Those conversations may reveal whether the problems are primarily operational, political, or both, and whether the 22nd director has the leverage to reverse them.